Interactions of antioestrogens and aromatase inhibitors

FORUM - Trends in Experimental and Clinical Medicine

Volumn 12, Issue 1, 2002, Pages 45-59

  Schmid, Peter ^a   Possinger, Kurt ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Antioestrogen; Aromatase inhibitor; Breast cancer; Interaction

Indexed keywords

4 HYDROXYANDROST 4 ENE 3,17 DIONE 4 ACETATE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROSTANE DERIVATIVE; ANTIESTROGEN; AROMATASE INHIBITOR; DANAZOL; DROLOXIFENE; ESTRADIOL; EXEMESTANE; FADROZOLE; FORMESTANE; FULVESTRANT; GONADORELIN DERIVATIVE; IDOXIFENE; LETROZOLE; NORTAMOXIFEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; VOROZOLE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENDOMETRIUM CANCER; ESTRADIOL BLOOD LEVEL; EVIDENCE BASED MEDICINE; HUMAN; NONHUMAN; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS; DRUG INTERACTIONS; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT;

EID: 0037003282     PISSN: 11218142     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women. N. Engl. J. Med. 1998; 319: 1681-1692.
2. Fisher B et al. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 1998; 90: 1371-1387.
3. Stockler M et al. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treatment Reviews 2000; 26: 151-168.
4. Howell A et al. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995; 345: 29-30.
5. Osborne CK. A Double-Blind Randomized Trial Comparing the Efficacy and Tolerability of Faslodex™ (Fulvestrant) with Arimidex™ (Anastrozole) in Post-Menopausal (PM) Women with Advanced Breast Cancer (ABC). Breast Cancer Res. Treat. 2000; 64: 27 (abs. 7).
6. Howell A et al. Comparison of Efficacy and Tolerability of Fulvestrant (Faslodex™) with Anastrozole (Arimidex™) in Post-Menopausal (PM) Women with Advanced Breast Cancer (ABC) -Preliminary Results. Breast Cancer Res. Treat. 2000; 64: 27 (abs. 6).
7. Fulvestrant (Faslodex) versus anastrozole (Arimidex) for the treatment of Advanced Breast Cancer in postmenopausal women - safety update on the combined analysis of two multicenter trials. Breast Cancer Res. Treat. 2001; 69: 290 (abs. 455).
8. Geisler J et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol. 2002; 20: 751-757.
9. Kaufmann M et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. J. Clin. Oncol. 2000; 18: 1399-1411.
10. Dombernowsky P et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol. 1998; 16: 453-461.
11. Gershanovich M et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann. Oncol. 1998; 9: 639-645.
12. Buzdar AU et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998; 83: 1142-1152.
13. Buzdar AU et al. A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 1997; 79: 730-739.
14. Jonat W et al. A randomized trial comparing two doses of the new selective aromatase inhibitor (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer 1996; 32A: 404-412.
15. Buzdar A et al. Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol Acetate. J. Clin. Oncol. 2001; 19: 3357-3366.
16. Milla-Santos A et al. Anastrozole Vs Tamoxifen in Hormonodependent Advanced Breast Cancer. A Phase II Randomized Trial. Breast Cancer Res. Treat. 2000; 64: (abs. 173).
17. Paridaens R et al. Promising Activity and Safety of Exemestane (E) as First-Line Hormonal Therapy (HT) in Metastatic Breast Cancer (MBC) Patients (pts): Final Results of an EORTC Randomised Phase II Trial. Breast Cancer Res. Treat. 2000; 64: (abs. 167).
18. Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. J. Clin. Oncol. 2000; 18: 3758-3767.
19. Bonneterre J et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J. Clin. Oncol. 2000; 18: 3748-3757.
20. Bonneterre J et al. Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma. Results of Two Randomized Trials Designed for Combined Analysis. Cancer 2001; 92: 2247-2258.
21. Mouridsen H et al. Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. 2001; 19: 2596-2606.
22. Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal women. 24th Annual San Antonio Breast Cancer Symposium 2001; #8.
23. Dixon JM et al. Letrozole as primary medical therapy for locally advanced and large breast cancer. Am. Soc. Clin. Oncol. 1998; 17: abs. 400.
24. Eiermann W et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann. Oncol. 2001; 12: 1527-1532.
25. Ellis MJ et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-Positive, estrogen receptor-positive primary breast cancer: Evidence from a Phase III randomised Trial. J. Clin. Oncol. 2001; 19: 3808-3816.
26. Jakesz R et al. Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four-year results of Austrian Breast Cancer Study Group (ABCSG) Trial 5. Am. Soc. Clin. Oncol. 1999; 18: 67a (abs. 250).
27. Roche HH et al. Complete Hormonal, Blockade Versus Chemotherapy in Premenopausal Early-Stage Breast Cancer Patients (Pts) with Positive Hormone-Receptor (HR+) and 1-3 Node-Positive (N+) Tumour: Results of the FASG 06 Trial. Am. Soc. Clin. Oncol. 2000; 19: (abs. 279).
28. Davidson N et al. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101). Am. Soc. Clin. Oncol. 1999; 18: 67a (abs. 249).
29. Boccardo F et al. Ovarian ablation versus goserelin with or without tamoxifen in premenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann. Oncol. 1994; 5: 337-342.
30. Jonat W et al. A randomized study to compare the effect of the luteinising hormone releasing (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur. J. Cancer 1995; 31A: 137-142.
31. Klijn JG et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J. Natl. Cancer Inst. 2000; 92: 903-911.
32. Klijn JG et al. Combined tamoxfen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J. Clin. Oncol. 2001; 19: 343-353.
33. Lien EA et al. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. 1990; 50: 5851-5857.
34. Dowsett M et al. The effect of anastrozole on the pharmacokinetics of tamoxifen in postmenopausal women with early breast cancer. Br. J. Cancer 1999; 79: 311-315.
35. The ATAC Trialists' Group. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a subgroup of the "Arimidex" and Tamoxifen Alone or in Combination (ATAC) trial. Br. J. Cancer 2001; 85: 317-324.
36. Ingle JN et al. Evaluation of Tamoxifen plus Letrozole with Assessment of Pharmacokinetic Interaction in Postmenopausal Women with Metastatic Breast Cancer. Clin. Cancer Res. 1999; 5: 1642-1649.
37. Dowsett M et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin. Cancer Res. 1999; 9: 2338-2343.
38. Brodie AMH et al. Aromatase inhibitors and their use in controlling oestrogen-dependent processes. J. Steroid Biochem. 1979; 11: 107.
39. Van Ginckel R et al. Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat. Cancer Chemother. Pharmacol. 1996; 38: 21-28.
40. Wilkinson JR et al. Response of nitrosomethylurea-induced rat mammary tumour to endocrine therapy and comparison with clinical response. Cancer Res. 1986; 46: 4862-4865.
41. Zaccheo T et al. Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats. J. Steroid Biochem. 1993; 44: 677-681.
42. Tominaga T et al. Effect of CGS/16949A plus tamoxifen on induced mammary tumours in rats. Eur. J. Cancer 1990; 26: 600-603.
43. Yue W et al. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res. 1994; 54: 5092-5095.
44. Yue W et al. Effect of Aromatase Inhibitors on Growth of Mammary Tumors in a Nude Mouse Model. Cancer Res. 1995; 55: 3073-3077.
45. Lu Q et al. The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res. Treat. 1998; 50: 63-71.
46. Lu Q et al. The effect of combining aromatase inhibitors with antiestrogens on tumour growth in a nude mouse model for breast cancer. Breast Cancer Res. Treat. 1999; 57: 183-192.
47. Brodie A et al. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. Oncology 1998; 12: 29-33.
48. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
49. Ragaz J. Combination of hormones for metastatic carcinoma of the breast: Aminoglutethimide plus Tamoxifen in combination versus Aminoglutethimide alone versus Tamoxifen alone. Rev. Endocr. Relat. Cancer 1981; 8: 547-563.
50. Smith I et al. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res. 1982; 42: 3430-3433.
51. Corkery J et al. Tamoxifen and aminoglutethimide in advanced breast cancer, Cancer Res. 1982; 42: 3409-3414.
52. Hisamatsu K et al. Aminoglutethimide and aminoglutethimide + tamoxifen. Gan to Kagaku Ryoho 1992; 19: 2017-2023.
53. Milsted R et al. A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer. Cancer Chemother. Pharmacol. 1985; 14: 272-273.
54. Powles TJ et al. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. Lancet 1984; 1: 1369-1372.
55. Rose C et al. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. Breast Cancer Res. Treat. 1986; 7: 45-50.
56. Alonso-Muñoz MC et al. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer. Oncology 1988; 45: 350-353.
57. Powles TJ et al. A double blind randomised clinical trial of adjuvant aminoglutethimide versus placebo given to post menopausal patients with histologically confirmed stage II breast cancer. Breast Cancer Res. Treat. 1986; 7: 37-40.
58. Jones AL et al. Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: Analysis at 8 years. J. Clin. Oncol. 1992; 10: 1547-1552.